These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 316585)

  • 1. High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand's disease and inhibitor.
    Bloom AL; Peake IR; Furlong RA; Davies BL
    Thromb Res; 1979; 16(5-6):847-52. PubMed ID: 316585
    [No Abstract]   [Full Text] [Related]  

  • 2. Failure of AHF concentration to control bleeding in von Willebrand's disease.
    Green D; Potter EV
    Am J Med; 1976 Mar; 60(3):357-60. PubMed ID: 1083144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy.
    Mannucci PM; Ruggeri ZM; Ciavarella N; Kazatchkine MD; Mowbray JF
    Blood; 1981 Jan; 57(1):25-31. PubMed ID: 6778538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement therapy in platelet-type von Willebrand disease.
    Takahashi H
    Am J Hematol; 1985 Apr; 18(4):351-62. PubMed ID: 3919572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type IIB von Willebrand's disease: unusual response to cryoprecipitate infusion.
    Weinger RS; Cimo PL; Moake JL; Olson JD; Heller MS
    Ann Intern Med; 1981 Jan; 94(1):47-50. PubMed ID: 6778284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand's disease.
    Br Med J; 1976 Sep; 2(6038):715-6. PubMed ID: 1086116
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of von Willebrand-Jürgens syndrome with "hepatitis-free" factor VIII concentrates].
    Köhler M; Hellstern P; Reiter B; Miyashita C; von Blohn G; Wenzel E
    Dtsch Med Wochenschr; 1984 Nov; 109(47):1800-5. PubMed ID: 6437785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
    Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic studies in von Willebrand's disease: alteration of factor VIII/von Willebrand protein after transfusion with plasma concentrates in patients with von Willebrand's disease.
    Sultan Y; Simeon J; Maisonneuve P; Caen JP
    Thromb Haemost; 1976 Feb; 35(1):110-9. PubMed ID: 1085498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease.
    Berntorp E; Nilsson IM
    Vox Sang; 1989; 56(4):212-7. PubMed ID: 2503935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the prolonged bleeding time in von Willebrand's disease.
    Smiley RK; Tittley P; Rock G
    Thromb Res; 1989 Mar; 53(5):417-26. PubMed ID: 2499940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the treatment of von Willebrand's disease.
    Sultan Y
    Prog Clin Biol Res; 1981; 72():149-62. PubMed ID: 6801684
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe von Willebrand's disease during labor and delivery.
    Lipton RA; Ayromlooi J; Coller BS
    JAMA; 1982 Sep; 248(11):1355-7. PubMed ID: 6809966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the severe bleeding episode in type III von Willebrand's disease by simultaneous administration of cryoprecipitate and platelet concentrate.
    Boda Z; Pfliegler G; Hársfalvi J; Rak K
    Blood Coagul Fibrinolysis; 1991 Dec; 2(6):775-7. PubMed ID: 1799664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of von Willebrand's disease and hypofibrinogenemia with single donor cryoprecipitate from plasma exchange donation.
    McLeod BC; McKenna R; Sassetti RJ
    Am J Hematol; 1989 Oct; 32(2):112-6. PubMed ID: 2787956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of post-infusion factor VIII in von Willebrand's disease.
    Muntz RH; Ekert H; Helliger H
    Thromb Res; 1974 Aug; 5(2):111-23. PubMed ID: 4547286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.